Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Stopping Cholesterol Drugs May Be… >

Stopping Cholesterol Drugs May Be Associated with Increased Risk of Parkinson's

Published: July 24, 2013.
Released by American Academy of Neurology  

MINNEAPOLIS – People who stop taking cholesterol drugs may be at an increased risk for developing Parkinson's disease, according to research that appears in the July 24, 2013, online issue of Neurology¬ the medical journal of the American Academy of Neurology. Previous studies on the relationship between cholesterol drugs called statins and the risk of Parkinson's disease have had inconsistent results.

The current study involved 43,810 people in Taiwan who were taking statins and did not have Parkinson's disease. Taiwan's compulsory national health insurance program reimbursement policy requests that doctors stop prescribing statins once the patient's cholesterol reaches the treatment goal, which is contrary to standard treatment in the United States.

"This policy allowed us to see whether there was any difference in the risk of Parkinson's in people who stopped taking statins compared to the ones who kept taking them," said study author Jou-Wei Lin, MD, PhD, of National Taiwan University in Taipei.

The study found a difference between two types of statins. The use of lipophilic, or fat-soluble, statins such as simvastatin and atorvastatin was associated with a reduced risk of Parkinson's, while no such association was found for hydrophilic, or water-soluble, statins such as pravastatin and rosuvastatin.

Those who stopped taking the fat-soluble statins were 58 percent more likely to develop Parkinson's disease than those who kept taking the drugs, an absolute risk of 2.65 cases per one million person-days. This result was consistent even after adjusting for other conditions such as diabetes and high blood pressure.

The study also looked at how many people taking the two types of statins developed Parkinson's disease, compared to the number of person-days spent on the medication to come up with an incidence rate. A total of 25 people taking fat-soluble statins developed Parkinson's from a total of nearly 15 million person-days on the drugs, for a rate of 1.68 cases per one million person-days on the drugs. For the water-soluble statins, 14 people developed Parkinson's from nearly four million person-days on the drugs, for a rate of 3.52 cases per one million person-days on the drugs.

"The fat-soluble statins are better able to cross the blood-brain barrier than the water-soluble statins," Lin said.




The above story is based on materials provided by American Academy of Neurology.

Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


comments powered by Disqus


Related »

Type 
5/26/10 
Some Statins Have Unintended Effects And Warrant Closer Monitoring, Study Finds
The type and dosage of statin drugs given to patients to treat heart disease should be proactively monitored as …
Vascular 
12/18/13 
An Apple a Day Keeps the Doctor Away
Prescribing an apple a day to all adults aged 50 and over would prevent or delay around 8,500 vascular …
Rheumatoid 
9/7/10 
Regular Statin Use Is Associated with a Reduced Risk of Developing Rheumatoid Arthritis
There is an association between taking statins (lipid lowering drugs), and reduced risk of developing the chronic inflammatory disease, …
Statins 
9/10/14 
The Lancet Diabetes & Endocrinology: Study Indicates That Statins May Protect Against Microvascular Complications of Diabetes
The development of common diabetes complications* that can lead to blindness and amputations could be reduced by taking statins, …
Vte 
5/16/10 
Statins Decrease Risk of Clot-related Diseases
ATS 2010, NEW ORLEANS— Individuals at risk for clot-related diseases may benefit from taking common cholesterol-lowering drugs known as …
Statins 
2/29/12 
American Heart Association Comment: FDA Announces Safety Changes on Labeling for Some Statins
The United States Food and Drug Administration (FDA) announced it is revising safety information on the labels of some …
Ldl-C 
9/1/13 
Statins Reduce CV Events in CAD Patients with Very Low LDL-C
Dr Nakano said: "Many randomised clinical trials, such as Treating to New Targets (TNT) and PROVE IT-TIMI, have shown …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile